---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-016281"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:23:04.314539+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn appoints Kristian Humer as CFO; notes upcoming pipeline milestones for 2024

## Summary
- Kristian Humer appointed CFO effective April 16, replacing interim CFO Stephen DiPalma.
- Compensation: $475k base salary, 40% target bonus, $87k signing bonus, 275k-share option award.
- Humer brings 14+ years life science financial strategy; previously CFO/CBO at Viridian Therapeutics.
- Lead program FHD-286 AML data expected H2 2024; FHD-909 (with Lilly) IND filing on track Q2 2024.

## SEC filing metadata
- accession: 0001628280-24-016281
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/0001628280-24-016281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/fhtx-20240416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-016281
- JSON: https://secwatch.observer/filing/0001628280-24-016281.json
- Plain text: https://secwatch.observer/filing/0001628280-24-016281.txt

## Key facts
- Executive change
  Stephen DiPalma departed as Interim Chief Financial Officer at Foghorn Therapeutics Inc..
  - Action: ceased to serve
  - Role: Interim Chief Financial Officer
  source text: In connection with Mr. Humer’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, will cease to serve in such roles.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/0001628280-24-016281-index.htm
- Executive change
  Kristian F. Humer was appointed as Chief Financial Officer at Foghorn Therapeutics Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On April 16, 2024, Foghorn Therapeutics Inc. (the “Company”) announced that Kristian F. Humer had been appointed to serve as the Company’s Chief Financial Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828024016281/0001628280-24-016281-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.